These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 22430044

  • 21. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone.
    Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT.
    Am J Clin Nutr; 2009 May; 89(5):1459-67. PubMed ID: 19321570
    [Abstract] [Full Text] [Related]

  • 22. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 23. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [Abstract] [Full Text] [Related]

  • 24. The association between serum dehydroepiandrosterone Sulphate (DHEA-S) level and bone mineral density in Korean men.
    Lee D, Kim H, Ahn SH, Lee SH, Bae SJ, Kim EH, Kim HK, Choe JW, Kim BJ, Koh JM.
    Clin Endocrinol (Oxf); 2015 Aug; 83(2):173-9. PubMed ID: 25692973
    [Abstract] [Full Text] [Related]

  • 25. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 26. Weak androgen levels, glucocorticoid therapy, and bone mineral density in postmenopausal women with rheumatoid arthritis.
    Fiter J, Nolla JM, Navarro MA, Gómez-Vaquero C, Rosel P, Mateo L, Roig-Escofet D.
    Joint Bone Spine; 2000 Jul; 67(3):199-203. PubMed ID: 10875318
    [Abstract] [Full Text] [Related]

  • 27. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM.
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [Abstract] [Full Text] [Related]

  • 28. [Efficiency of calcium and vitamin D3 in the treatment of steroid osteoporosis in patients with hormone dependent bronchial asthma].
    Ememl'ianov AV, Shevelev SE, Murzin BA, Amosov VI.
    Ter Arkh; 1999 May; 71(11):68-9. PubMed ID: 10626343
    [Abstract] [Full Text] [Related]

  • 29. [Introduction: Patients with primary adrenal insufficiency receive long - term glucocorticoid replacement therapy, which may cause osteoporosis].
    Vaňuga P, Ságová I.
    Vnitr Lek; 2021 May; 67(5):264-269. PubMed ID: 35459392
    [Abstract] [Full Text] [Related]

  • 30. The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women.
    Osmanagaoglu MA, Okumuş B, Osmanagaoglu T, Bozkaya H.
    J Womens Health (Larchmt); 2004 Nov; 13(9):993-9. PubMed ID: 15665656
    [Abstract] [Full Text] [Related]

  • 31. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus.
    Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH.
    Arthritis Rheum; 2004 Nov; 50(11):3591-5. PubMed ID: 15529389
    [Abstract] [Full Text] [Related]

  • 32. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial.
    Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK.
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4650-6. PubMed ID: 11134123
    [Abstract] [Full Text] [Related]

  • 33. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA supplementation of bone mineral density in healthy adults.
    Lin H, Li L, Wang Q, Wang Y, Wang J, Long X.
    Gynecol Endocrinol; 2019 Nov; 35(11):924-931. PubMed ID: 31237150
    [Abstract] [Full Text] [Related]

  • 34. Sex-specific association of serum dehydroepiandrosterone and its sulfate levels with osteoporosis in type 2 diabetes.
    Li S, Li W, Chang L, Wan J, Chen S, Zhang X, He Q, Liu M.
    J Bone Miner Metab; 2024 May; 42(3):361-371. PubMed ID: 38769209
    [Abstract] [Full Text] [Related]

  • 35. Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism.
    Földes J, Lakatos P, Zsadányi J, Horváth C.
    Eur J Endocrinol; 1997 Mar; 136(3):277-81. PubMed ID: 9100552
    [Abstract] [Full Text] [Related]

  • 36. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus.
    Formiga F, Moga I, Nolla JM, Navarro MA, Bonnin R, Roig-Escofet D.
    Clin Exp Rheumatol; 1997 Mar; 15(4):387-92. PubMed ID: 9272299
    [Abstract] [Full Text] [Related]

  • 37. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts.
    Takayanagi R, Goto K, Suzuki S, Tanaka S, Shimoda S, Nawata H.
    Mech Ageing Dev; 2002 Apr 30; 123(8):1107-14. PubMed ID: 12044960
    [Abstract] [Full Text] [Related]

  • 38. Prevention of corticosteroid-induced osteoporosis by alfacalcidol.
    Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, Speer G, Bossanyi A.
    Z Rheumatol; 2000 Apr 30; 59 Suppl 1():48-52. PubMed ID: 10769437
    [Abstract] [Full Text] [Related]

  • 39. Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation?
    Lespessailles E, Poupon S, Adriambelosoa N, Pothuaud L, Siroux V, Bouillon S, Benhamou CL.
    Joint Bone Spine; 2000 Apr 30; 67(2):119-26. PubMed ID: 10769104
    [Abstract] [Full Text] [Related]

  • 40. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial.
    Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK.
    J Clin Endocrinol Metab; 2008 Feb 30; 93(2):400-9. PubMed ID: 18000094
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.